Retraction: Epithelial-Mesenchymal Transition Markers and HER3 Expression Are Predictors of Elisidepsin Treatment Response in Breast and Pancreatic Cancer Cell Lines (PLoS ONE (2013) 8: 1 (e53645) DOI: 10.1371/journal.pone.0053645);Epithelial-Mesenchymal Transition Markers and HER3 Expression Are Predictors of Elisidepsin Treatment Response in Breast and Pancreatic Cancer Cell Lines

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Teixidó, Cristina ^a   Marés, Rosó ^a   Aracil, Miguel ^b   Ramón y Cajal, Santiago ^c   Hernández Losa, Javier ^c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b PHARMAMAR S A   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ELISIDEPSIN; EPIDERMAL GROWTH FACTOR RECEPTOR 3; SHORT HAIRPIN RNA; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RESPONSE; DRUG SENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; IC 50; IN VITRO STUDY; PANCREAS CANCER; PHENOTYPE; PROTEIN EXPRESSION; STABLE EXPRESSION;

EID: 84872193001     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0298557     Document Type: Erratum

References (42)

1. Hamann MT, Otto CS, Scheuer PJ, Dunbar DC, (1996) Kahalalides: Bioactive Peptides from a Marine Mollusk Elysia rufescens and Its Algal Diet Bryopsis sp.(1). J Org Chem 61: 6594-6600.
2. Wosikowski K, Schuurhuis D, Johnson K, Paull KD, Myers TG, et al. (1997) Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst 89: 1505-1515.
3. Gomez SG, Bueren JA, Faircloth GT, Jimeno J, Albella B, (2003) In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells. Exp Hematol 31: 1104-1111.
4. Suarez Y, Gonzalez L, Cuadrado A, Berciano M, Lafarga M, et al. (2003) Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol Cancer Ther 2: 863-872.
5. Ling YH, Aracil M, Jimeno J, Perez-Soler R, Zou Y, (2009) Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer 45: 1855-1864.
6. Varadi T, Roszik J, Lisboa D, Vereb G, Molina-Guijarro JM, et al. (2011) ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment. Eur J Pharmacol 667: 91-99.
7. Sewell JM, Mayer I, Langdon SP, Smyth JF, Jodrell DI, et al. (2005) The mechanism of action of Kahalalide F: variable cell permeability in human hepatoma cell lines. Eur J Cancer 41: 1637-1644.
8. Molina-Guijarro JM, Macias A, Garcia C, Munoz E, Garcia-Fernandez LF, et al. (2011) Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells. PLoS One 6: e19042.
9. Varadi T, Roszik J, Lisboa D, Vereb G, Molina-Guijarro JM, et al. (2011) ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment. Eur J Pharmacol 667: 91-99.
10. Janmaat ML, Rodriguez JA, Jimeno J, Kruyt FA, Giaccone G, (2005) Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol Pharmacol 68: 502-510.
11. Teixido C, Arguelaguet E, Pons B, Aracil M, Jimeno J, et al. (2012) ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines. Int J Oncol.
12. Huber MA, Kraut N, Beug H, (2005) Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17: 548-558.
13. Thiery JP, (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454.
14. Thiery JP, (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15: 740-746.
15. Polyak K, Weinberg RA, (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273.
16. Yamashita S, Miyagi C, Fukada T, Kagara N, Che YS, et al. (2004) Zinc transporter LIVI controls epithelial-mesenchymal transition in zebrafish gastrula organizer. Nature 429: 298-302.
17. Nagar B, Overduin M, Ikura M, Rini JM, (1996) Structural basis of calcium-induced E-cadherin rigidification and dimerization. Nature 380: 360-364.
18. Shapiro L, Fannon AM, Kwong PD, Thompson A, Lehmann MS, et al. (1995) Structural basis of cell-cell adhesion by cadherins. Nature 374: 327-337.
19. Nagafuchi A, Shirayoshi Y, Okazaki K, Yasuda K, Takeichi M, (1987) Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA. Nature 329: 341-343.
20. Patel DJ, Gumbiner BM, (1995) Cell-cell recognition. Zipping together a cell adhesion interface. Nature 374: 306-307.
21. Cavey M, Rauzi M, Lenne PF, Lecuit T, (2008) A two-tiered mechanism for stabilization and immobilization of E-cadherin. Nature 453: 751-756.
22. Hazan RB, Qiao R, Keren R, Badano I, Suyama K, (2004) Cadherin switch in tumor progression. Ann N Y Acad Sci 1014: 155-163.
23. Schmalhofer O, Brabletz S, Brabletz T, (2009) E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 28: 151-166.
24. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G, (1998) A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392: 190-193.
25. Peinado H, Olmeda D, Cano A, (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7: 415-428.
26. Moreno-Bueno G, Cubillo E, Sarrio D, Peinado H, Rodriguez-Pinilla SM, et al. (2006) Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res 66: 9543-9556.
27. Thiery JP, Sleeman JP, (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142.
28. Thiery JP, Acloque H, Huang RY, Nieto MA, (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
29. Nyholm PG, Pascher I, Sundell S, (1990) The effect of hydrogen bonds on the conformation of glycosphingolipids. Methylated and unmethylated cerebroside studied by X-ray single crystal analysis and model calculations. Chem Phys Lipids 52: 1-10.
30. Garcia-Rocha M, Bonay P, Avila J, (1996) The antitumoral compound Kahalalide F acts on cell lysosomes. Cancer Lett 99: 43-50.
31. Hama H, Young DA, Radding JA, Ma D, Tang J, et al. (2000) Requirement of sphingolipid alpha-hydroxylation for fungicidal action of syringomycin E. FEBS Lett. 478: 26-28.
32. Shilabin AG, Kasanah N, Wedge DE, Hamann MT, (2007) Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies. J Med Chem 50: 4340-4350.
33. Herrero AB, Astudillo AM, Balboa MA, Cuevas C, Balsinde J, et al. (2008) Levels of SCS7/FA2H-mediated fatty acid 2-hydroxylation determine the sensitivity of cells to antitumor PM02734. Cancer Res 68: 9779-9787.
34. Blume-Jensen P, Hunter T, (2001) Oncogenic kinase signalling. Nature 411: 355-365.
35. Ciardiello F, Kim N, Saeki T, Dono R, Persico MG, et al. (1991) Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci U S A 88: 7792-7796.
36. Friess H, Yamanaka Y, Kobrin MS, Do DA, Buchler MW, et al. (1995) Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin Cancer Res 1: 1413-1420.
37. Koumakpayi IH, Diallo JS, Le Page C, Lessard L, Gleave M, et al. (2006) Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res 12: 2730-2737.
38. Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, et al. (2006) Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. Cancer J 12: 229-236.
39. Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, et al. (1992) Expression of the ERBB3 gene product in breast cancer. Br J Cancer 66: 1116-1121.
40. Lozano JJ, Soler M, Bermudo R, Abia D, Fernandez PL, et al. (2005) Dual activation of pathways regulated by steroid receptors and peptide growth factors in primary prostate cancer revealed by Factor Analysis of microarray data. BMC Genomics 6: 109.
41. Naidu R, Yadav M, Nair S, Kutty MK, (1998) Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 78: 1385-1390.
42. Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, et al. (2006) ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 24: 4317-4323.